CA3023630A1 - Nicotine particles and compositions - Google Patents

Nicotine particles and compositions Download PDF

Info

Publication number
CA3023630A1
CA3023630A1 CA3023630A CA3023630A CA3023630A1 CA 3023630 A1 CA3023630 A1 CA 3023630A1 CA 3023630 A CA3023630 A CA 3023630A CA 3023630 A CA3023630 A CA 3023630A CA 3023630 A1 CA3023630 A1 CA 3023630A1
Authority
CA
Canada
Prior art keywords
nicotine
particle
particles
amino acid
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3023630A
Other languages
English (en)
French (fr)
Inventor
Gerard Zuber
Nicolo VOLPE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philip Morris Products SA
Original Assignee
Philip Morris Products SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products SA filed Critical Philip Morris Products SA
Publication of CA3023630A1 publication Critical patent/CA3023630A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
CA3023630A 2016-06-30 2017-06-14 Nicotine particles and compositions Abandoned CA3023630A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16177163.9 2016-06-30
EP16177163 2016-06-30
PCT/IB2017/053543 WO2018002756A1 (en) 2016-06-30 2017-06-14 Nicotine particles and compositions

Publications (1)

Publication Number Publication Date
CA3023630A1 true CA3023630A1 (en) 2018-01-04

Family

ID=56296661

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023630A Abandoned CA3023630A1 (en) 2016-06-30 2017-06-14 Nicotine particles and compositions

Country Status (19)

Country Link
US (2) US20190133940A1 (https=)
EP (1) EP3478264B1 (https=)
JP (2) JP2019524648A (https=)
KR (1) KR102523677B1 (https=)
CN (1) CN109310622A (https=)
AR (1) AR108920A1 (https=)
AU (1) AU2017286864A1 (https=)
CA (1) CA3023630A1 (https=)
ES (1) ES3055891T3 (https=)
IL (1) IL263355A (https=)
MX (1) MX385972B (https=)
PH (1) PH12018502714A1 (https=)
PL (1) PL3478264T3 (https=)
RU (1) RU2767064C2 (https=)
SG (1) SG11201809594WA (https=)
TW (1) TW201801716A (https=)
UA (1) UA124535C2 (https=)
WO (1) WO2018002756A1 (https=)
ZA (1) ZA201806949B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3055891T3 (en) * 2016-06-30 2026-02-16 Philip Morris Products Sa Nicotine particles and compositions
WO2020071448A1 (ja) * 2018-10-02 2020-04-09 学校法人名城大学 吸入粉末剤、その評価方法及びその用途
EP3946262B1 (en) * 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
CN110384700A (zh) * 2019-09-03 2019-10-29 云南喜科科技有限公司 一种合成尼古丁的组合物
UA130281C2 (uk) 2019-11-14 2026-01-07 Філіп Морріс Продактс С.А. Сухий порошковий склад зі смаком тютюну, спосіб його одержання та порошкова система
KR20220119101A (ko) 2019-12-19 2022-08-26 쥴 랩스, 인크. 유기 기반 니코틴 겔 조성물
EP4076026A1 (en) 2019-12-19 2022-10-26 Juul Labs, Inc. Metal oxide-based gel nicotine compositions
CA3164639A1 (en) 2019-12-20 2021-06-24 Juul Labs, Inc. Hydrated ionic clay and tobacco material compositions
WO2021201258A1 (ja) * 2020-04-01 2021-10-07 株式会社ＳｔａｔｅＡｒｔ 核酸含有組成物、核酸含有組成物の製造方法及び核酸導入方法
ES3040112T3 (en) * 2020-06-15 2025-10-28 Philip Morris Products Sa Anatabine powder compositions
BR112023003114A2 (pt) * 2020-09-03 2023-04-04 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade liofilizadas
WO2022049488A1 (en) * 2020-09-03 2022-03-10 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
US12594238B2 (en) * 2020-09-03 2026-04-07 Philip Morris Products S.A. Low hygroscopicity active powder compositions
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2231968A1 (en) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
SK11142002A3 (sk) * 1999-12-30 2004-09-08 Chiron Corporation Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
CA2418960A1 (en) * 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
MX2007004495A (es) * 2004-10-15 2007-05-10 Pfizer Prod Inc Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
FI20060428A7 (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
CA2944471C (en) * 2014-04-08 2020-03-31 Philip Morris Products S.A. Nicotine formulations and methods of making the same
CA2943746C (en) * 2014-04-28 2023-08-15 Philip Morris Products S.A. Flavoured nicotine powder inhaler
US10149844B2 (en) * 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
ES3055891T3 (en) * 2016-06-30 2026-02-16 Philip Morris Products Sa Nicotine particles and compositions
PL3478265T3 (pl) * 2016-06-30 2025-04-14 Philip Morris Products S.A. Cząstki nikotyny
IL269275B2 (en) * 2017-06-28 2023-04-01 Philip Morris Products Sa Container with particles for use with an inhaler

Also Published As

Publication number Publication date
AU2017286864A1 (en) 2018-11-15
IL263355A (en) 2018-12-31
ZA201806949B (en) 2019-07-31
JP2019524648A (ja) 2019-09-05
AR108920A1 (es) 2018-10-10
MX385972B (es) 2025-03-18
RU2018145313A (ru) 2020-07-30
EP3478264C0 (en) 2025-11-19
MX2018015118A (es) 2019-04-15
RU2767064C2 (ru) 2022-03-16
EP3478264A1 (en) 2019-05-08
RU2021132299A (ru) 2021-12-10
ES3055891T3 (en) 2026-02-16
SG11201809594WA (en) 2018-11-29
TW201801716A (zh) 2018-01-16
KR102523677B1 (ko) 2023-04-20
US20210361567A1 (en) 2021-11-25
PH12018502714A1 (en) 2019-07-29
PL3478264T3 (pl) 2026-02-02
UA124535C2 (uk) 2021-10-05
JP2022071106A (ja) 2022-05-13
WO2018002756A1 (en) 2018-01-04
EP3478264B1 (en) 2025-11-19
US20190133940A1 (en) 2019-05-09
CN109310622A (zh) 2019-02-05
KR20190025824A (ko) 2019-03-12
RU2018145313A3 (https=) 2020-07-30
BR112018076215A2 (pt) 2019-03-26

Similar Documents

Publication Publication Date Title
US20210361567A1 (en) Nicotine particles and compositions
US12048762B2 (en) Nicotine particles
AU2001281113B2 (en) Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US20050013867A1 (en) Use of proton sequestering agents in drug formulations
JP2004517127A (ja) ポリエン抗真菌剤の肺送達
WO2003035028A1 (en) Modulating charge density to produce improvements in the characteristics of spray-dried proteins
Adhikari et al. Amino acids improve aerosolization and chemical stability of potential inhalable amorphous Spray-dried ceftazidime for Pseudomonas aeruginosa lung infection
JP2013082660A (ja) ニコチン薬の製造法およびその方法により製造される医薬
RU2847582C2 (ru) Никотиносодержащие частицы и композиции
NZ747471A (en) Nicotine particles and compositions
BR112018076215B1 (pt) Partículas compreendendo sal de nicotina, composições compreendendo as mesmas e método de preparação
NZ747726A (en) Nicotine particles
JP2025500933A (ja) 慢性肺疾患の治療のための吸入可能又は摂取可能な乳酸組成物
CN112043687A (zh) 一种治疗哮喘的吸入粉雾剂及其制备方法
HK40084007A (en) Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221214